Palvella Therapeutics, Inc. (PVLA)
Nasdaq · Healthcare · Biotechnology
$132.16−0.23%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.9B
- 52-week range
- $65.93 – $161.38
- 52-week change
- +87.32%
- EPS (trailing)
- −$4.85
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$41.7M
- Diluted EPS
- −$3.71
From the company’s annual report on SEC EDGAR.
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Headquarters: Wayne, United States · 29 employees · palvellatx.com